Bupranolol
![]() |
|
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral, topical (eye drops) |
ATC code | C07AA19 (WHO) |
Pharmacokinetic data | |
Bioavailability | < 10% |
Protein binding | 76% |
Metabolism | First pass elimination > 90% |
Biological half-life | 2-4 hours (plasma) |
Excretion | > 88% renal (as carboxybupranolol) |
Identifiers | |
|
|
CAS Number | 23284-25-5 ![]() |
PubChem (CID) | 2475 |
IUPHAR/BPS | 550 |
DrugBank | DB08808 ![]() |
ChemSpider | 2381 ![]() |
UNII | 858YGI5PIT ![]() |
KEGG | D07590 ![]() |
ChEMBL | CHEMBL305380 ![]() |
Chemical and physical data | |
Formula | C14H22ClNO2 |
Molar mass | 271.78298 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.
Contents
Uses and dosage[edit]
Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.
Pharmacology[edit]
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.
Adverse effects, contraindications, interactions[edit]
Adverse effects, contraindications and interactions are similar to other beta blockers.
References[edit]
- Dinnendahl, V; Fricke, U, eds. (2007). Arzneistoff-Profile (in German). 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.